* Nelfinavir mesylate
(NFV, Viracept), Agouron Pharmaceuticals Approved March 14, 1997 for the treatment of HIV infection when antiretroviral therapy is warranted in adults and pediatrics greater than or equal to 2 years old.
reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models.
 The present study was undertaken to evaluate the efficacy of bromocriptine mesylate
in maximal recommended dose as an add-on therapy to two oral antidiabetic drugs.
Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate
, nilotinib, and dasatinib.
The US Food & Drug Administration (FDA) approved it in its first formulation (saquinavir hard-gel, saquinavir mesylate
or Invirase) for use in combination with nucleoside reverse transcriptase inhibitors (NRTIs) in December 1995.
(BSE: 500124) (NYSE: RDY) has launched matinib Mesylate
Tablets, USP, a therapeutic equivalent generic version of Gleevec (imatinib mesylate
) Tablets in the United States market approved by the US Food and Drug Administration (USFDA), the company said.
Mylan NV (NASDAQ, TASE: MYL), a global pharmaceutical company, announced on Friday that it has launched its Imatinib Mesylate
Tablets, 100 mg and 400 mg, a generic version of Novartis's Gleevec Tablets, in the United States.
(known as MSD outside of the United States and Canada) to increase the target number of enrolled patients in a Phase Ib/II clinical study of its in-house discovered and developed microtubule dynamics inhibitor eribulin mesylate
(product name: Halaven, "eribulin") in combination with anti-PD-1 therapy pembrolizumab (brand name: KEYTRUDA) developed by Merck & Co., Inc., Kenilworth, NJ, U.S.A., for the treatment of triple-negative breast cancer, due to encouraging initial data.
has gained Food and Drug Administration approval of Pradaxa (dabigatran etexilate mesylate
) for the prophylaxis of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have had hip replacement surgery.
Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate
is frequently characterized by trisomy 8.
Cycloset, a quick-release oral formulation of bromocriptine mesylate
, was recently approved by the Food and Drug Administration as a treatment for type 2 diabetes, according to the manufacturers, VeroScience and S2 Therapeutics Inc.
The drug, imatinib mesylate
, which is marketed as Gleevec, is an enzyme suppressor.